Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide - 4Moving Biotech

Next Previous
Drug Profile

Liraglutide - 4Moving Biotech

Alternative Names: 4P 004

Latest Information Update: 28 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; Sorbonne University
  • Developer 4Moving Biotech; 4P-Pharma
  • Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis; Synovitis

Most Recent Events

  • 28 Sep 2025 No recent reports of development identified for phase-I development in Osteoarthritis in Belgium (Intra-articular, Injection)
  • 17 Jun 2025 Phase-II clinical trials in Osteoarthritis (Treatment-experienced) in Spain, Poland, France, Denmark, Canada (Intra-articular) (NCT07225829) (CTIS2024-518916-38-00)
  • 17 Jun 2025 Phase-II clinical trials in Synovitis (Treatment-experienced) in Spain, Denmark, Poland, France, Canada, USA (Intra-articular) (NCT07225829) (CTIS2024-518916-38-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top